Background. This study tests the efficacy of an angiogenic growth factor, endothelial cell growth factor,
T he number of people who suffer from lowerextremity ischemia is increasing with a corresponding increase in the need for limb salvage vascular surgery.' Currently, severe chronic limb ischemia is treated by a variety of arterial revascularization techniques, including bypass procedures using autogenous and synthetic conduits, endarterectomy, and percutaneous techniques such as balloon angioplasty and atherectomy. Unfortunately, about 20% of patients with limb-threatening ischemia have disease that is so extensive that direct revascularization procedures cannot be undertaken successfully.2 Too often, the only alternative for these patients is limb amputation with its attendant morbidity and mortality.
A number of innovative approaches have been reported clinically and experimentally. These include pedal vessel bypass,3 conventional bypass with adjunctive distal arteriovenous fistula,45 staged arteriovenous reversal,6-9 omental or muscle flap transfer,10~12 and others. 13 However, the effectiveness and practicality of all such procedures have yet to be clearly established. Powerful testament to the size of the problem that remains comes from the Maryland study by Tunis et al, '4 which growth factor, would significantly improve perfusion in a rabbit ischemic hindlimb model.
Methods
Animal Hindlimb Ischemic Model Twenty-two adult New Zealand White male rabbits (mean weight, 4 kg) were studied. All animals were anesthetized with ketamine (50 mg/kg i.m.) and xylazine (5 mg/kg i.m.), and a longitudinal incision was made in the left groin from the inguinal ligament to above the knee. With the aid of surgical loops, the femoral artery was dissected, and its branches, the profunda, the lateral circumflex, and the superficial epigastric were exposed as completely as possible. The proximal popliteal and saphenous arteries also were dissected free. Ischemia then was induced in the left hindlimb by ligation of the distal external iliac artery just above the inguinal ligament, the inferior epigastric artery, all the branches of the femoral artery, and the proximal popliteal and saphenous arteries. This was followed by excision of the common and superficial femoral arteries (Fig 1) . All animals received 50 mL of 0.9% sodium chloride during surgery and cefazolin (15 
(L/R ratio).
Calf radioisotopic perfusion scan. Arterial perfusion was determined radioisotopically using 9"nTc macroaggregates that measured 15 to 30 ,um in diameter (E.I. du Pont de Nemours & Co., Boston, Mass). The aggregates are designed to be so large that they will be trapped in the capillary bed. With the animal under anesthesia, the left ventricle was punctured through the fourth intercostal space, and 1 mCi of 99"Tc macroaggregates in 2 mL saline was injected. After the injection, the limbs of the animal were scanned and counted on a gamma camera (Omega 500, Technicare Co., Cleveland, Ohio) that was interfaced to an MCS 560 computer system. The accumulated counts were stored on a disk for later retrieval and analysis. At that time, the radioactive counts from each calf were generated from corresponding regions of interest, and the ratio of the counts between the calves (L/R ratio) was calculated as an index of relative calf perfusion.
Angiography. Angiograms were performed using standard techniques. Two animals were studied for each group at postoperative day 20, and four from each group were studied at day 40. With the animals under anesthesia, the left common carotid artery was exposed through a ventral incision in the neck. By the Seldinger Comparison of calf blood pressure ratios (L/R ratio) determined by Doppler demonstrated no difference between the two groups on postoperative day 0 or 10. In both, severe ischemia was evident on postoperative day 10 in the left hindlimb compared with preoperative day 0 (P<.0001). However, as shown in Table 1 , on all subsequent examinations, although the ratio rose progressively in both groups, the value in group 1 always was substantially higher than in group 2, with the differences easily statistically significant (P<.0001).
The results of the radionuclide perfusion study are given in (Fig 2B) but virtually absent in those in group 2 (Fig 3B) .
The angiograms performed at the end of the study (day 40) also are of considerable interest, again demonstrating substantially more distal arterial reconstitution of the left hindlimb in group 1 animals (Fig 4A) than in group 2 animals (Fig 5A) . In addition, more collateral vessels were present in group 1 Quantitative analysis of new vessel formation in the left thigh at day 40 demonstrated more than twice the number of nutrient vessels in group 1 than in group 2 animals (23.8±3.4 versus 9.0± 1.5, P<.007).
Discussion
Biotechnology makes it possible to isolate and purify factors that can stimulate new blood vessel growth or angiogenesis.'819 In the present study, several techniques were used to examine and quantify limb perfusion. The results were consistent throughout; in every instance, substantially improved perfusion and revascularization were seen in the group that received the angiogenic factor during the postoperative period.
The agent used in the present study is one of the heparin-binding growth factors. This group has been divided into a basic fibroblast growth factor and an acidic fibroblast growth factor. The genes and protein structure of the two forms are similar, and they bind to the same receptor. 29.30 In most systems examined, basic fibroblast growth factor is-from 10-to 100-fold more potent than acidic fibroblast growth factor. 31 Although heparin has been shown to promote angiogenesis in a large-animal model following continuous intravascular infusion,32 the apparent dose required far exceeded (2x104 units per animal) that used in this study (0.4 units per injection). It is highly unlikely, therefore, that the angiogenic effect we observed was related to the small amount of heparin that was bound to the endo- thelial cell growth factor. On the other hand, in the presence of heparin, the ability of acidic fibroblast growth factor to stimulate endothelial cell proliferation increases 100-fold,31 and under these circumstances, the ED50 of acidic fibroblast growth factor is just about the same as basic fibroblast growth factor.33 In the present study, we used endothelial cell growth factor, which is an acidic fibroblast growth factor. We did so because it is cheaper than basic fibroblast growth factor and is available commercially bound to heparin, so we believed it was likely to be efficacious. Larger doses also could be administered. The doses of the endothelial cell growth factor used in this study were based on previous experience obtained during in vivo studies by Thompson et a120 and Andrade et al. 24 The format and schedule of administration of the agent were based on Goldsmith's lipid angiogenic factor study23 as well as preliminary experience from our laboratory.34 Administration of the agent was delayed to postoperative day 11 to minimize confounding effects of the host response to acute ischemic injury and the surgical procedure.
Angiogenesis is a complex process involving capillaries and venules, and the exact mechanism by which it was achieved in this study remains newly formed or just enlarged pre-existing vessels still presents a challenge.
The cellular events in the new vessel formation process currently are thought to be under the control of locally acting growth factors. The study by Mooney et Some evidence is now available, however, with regard to both the heart and hindlimbs. Banai et al,42 for example, were unable to demonstrate benefit from delivery of an acidic fibroblast growth factor to ischemic myocardium from an epicardial sponge when regional ischemia was produced gradually by application of an anaeroid constrictor to the left anterior descending coronary artery. By contrast, Yanagisawa-Miwa et a143 demonstrated significantly enhanced collateralization with intracoronary injection of a basic fibroblast growth factor. The first report, however, of successful revascularization of the ischemic hindlimb due to administration of an angiogenic factor came from our laboratory,44 an observation that since has been confirmed by Baffour and colleagues using, however, a basic fibroblast growth factor. 45 Clearly much remains to be done to further clarify and confirm the efficacy of this approach to limb as well as other tissue revascularization. In addition, the safety and potential adverse effects of administration of such agents must be assessed because the animals in the present study were not systematically assessed for evidence of hematological, renal, or hepatic toxicity after administration of endothelial cell growth factor. Nevertheless, given this present evidence of in vivo efficacy and the obvious need to improve our therapy of severe arterial insufficiency in patients, clinical application in the future of angiogenic agents similar to this should be considered a real possibility. 
